- Home
- QTTB vs FGNX Comparison
QTTB vs FGNX Comparison
Compare QTTB & FGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QTTB
- FGNX
- Stock Information
- Founded
- QTTB 2015
- FGNX 1932
- Country
- QTTB United States
- FGNX United States
- Employees
- QTTB N/A
- FGNX N/A
- Industry
- QTTB Biotechnology: Pharmaceutical Preparations
- FGNX Property-Casualty Insurers
- Sector
- QTTB Health Care
- FGNX Finance
- Exchange
- QTTB Nasdaq
- FGNX Nasdaq
- Market Cap
- QTTB 23.3M
- FGNX 25.2M
- IPO Year
- QTTB N/A
- FGNX N/A
- Fundamental
- Price
- QTTB $1.85
- FGNX $6.88
- Analyst Decision
- QTTB Hold
- FGNX
- Analyst Count
- QTTB 8
- FGNX 0
- Target Price
- QTTB $24.00
- FGNX N/A
- AVG Volume (30 Days)
- QTTB 83.8K
- FGNX 144.2K
- Earning Date
- QTTB 11-06-2025
- FGNX 08-07-2025
- Dividend Yield
- QTTB N/A
- FGNX N/A
- EPS Growth
- QTTB N/A
- FGNX N/A
- EPS
- QTTB N/A
- FGNX 2.41
- Revenue
- QTTB N/A
- FGNX $24,184,000.00
- Revenue This Year
- QTTB N/A
- FGNX N/A
- Revenue Next Year
- QTTB N/A
- FGNX N/A
- P/E Ratio
- QTTB N/A
- FGNX $3.25
- Revenue Growth
- QTTB N/A
- FGNX 24.03
- 52 Week Low
- QTTB $1.35
- FGNX $6.68
- 52 Week High
- QTTB $53.17
- FGNX $41.25
- Technical
- Relative Strength Index (RSI)
- QTTB 50.81
- FGNX N/A
- Support Level
- QTTB $1.62
- FGNX N/A
- Resistance Level
- QTTB $2.00
- FGNX N/A
- Average True Range (ATR)
- QTTB 0.14
- FGNX 0.00
- MACD
- QTTB 0.02
- FGNX 0.00
- Stochastic Oscillator
- QTTB 60.53
- FGNX 0.00
About QTTB Q32 Bio Inc. Common Stock
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.